top of page

Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma

  • blonca9
  • May 6
  • 1 min read

Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and Biomedical, the opporutnity to convert to equity in three years. He also provides an update on the progress of dosing renal cell carcinoma patients in the clinic, and what we can expect from the trial throughout the rest of the year.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page